Phase I clinical trial of RNDO-564
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs RNDO 564 (Primary)
- Indications Bladder cancer
- Focus First in man; Therapeutic Use
- 25 Nov 2024 New trial record
- 19 Nov 2024 According to a Rondo Therapeutics media release, RNDO-564 is slated for IND filing in Q3 2025.
- 19 Nov 2024 According to a Rondo Therapeutics media release, company is planning to start a trial at the end of 2025.